Group items tagged

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions Initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Also listed under R01.

The Rivkin Center is announcing funds for Scientific Scholar Awards to be allocated based on scientific merit. Scientific Scholar Awards are intended to assist promising laboratory and clinical scientists in pursuing a career as an independent investigator in ovarian cancer research. The two-year awards will provide a total of $120,000 in funding.

The Melanoma Research Alliance (MRA) is pleased to announce the Second Release of its Request for Proposals (RFP) for pre-clinical, translational, and early clinical research with the potential to produce unusually high impact, near-term advancements in melanoma prevention, detection, diagnosis, staging, and treatment.  The 2020 - 2021 award cycle, is anticipated to support at least $7.6 million in new funding. Proposals will be accepted for Established Investigator, Academic-Industry Partnership, Young Investigator, and Pilot Awards.  This Second Release includes two new Special Opportunity awards focused on Melanoma Brain Metastasis, in partnership with the Rising Tide Foundation for Clinical Cancer Research. Other Special Opportunities include: Pediatric Melanoma Young Investigator Award with St. Baldrick's Foundation, UK or Israel-Based Young Investigator Award with Rosetrees Trust, Radiation Oncology Young Investigator Award with ASTRO (U.S. applicants only), and Immunotherapy Young Investigator Awards supported by Bristol Myers Squibb (BMS).

The Rivkin Center is announcing funds for Pilot Study Awards to be allocated based on scientific merit. Pilot Study Awards support investigator-initiated projects in all areas of ovarian cancer research. In addition, projects designed to analyze data from already funded clinical trials will be considered. The two-year awards will provide a total of $75,000 in funding, with the possibility of an additional $25,000 awarded in year two, upon evaluation of year one progress, contingent on availability of funds.

In November 2018, the Moore Foundation announced its Diagnostic Excellence Initiative with a focus on diagnostic performance improvement. The initiative aims to reduce harm from erroneous or delayed diagnoses, reduce costs and redundancy in the diagnostic process, improve health outcomes and save lives. The initiative's first area of focus is to develop and validate new measures for diagnostic performance. Examples of our first cohort of grants for diagnostic clinical quality measures are now available for review. Starting with measure development is important - currently, U.S. health care systems are unable to systemically measure diagnostic performance in real time, which limits the ability to quantify performance and guide improvements. 

The NIH Director's New Innovator Award Program supports early stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research.

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) as a part of its Beau Biden Cancer Moonshot Initiative invites submission of applications requesting support for projects that will accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) as Recommendation I: Generation of Human Tumor Atlases. The overarching goal of this FOA is to accelerate research efforts conducted and led by the Human Tumor Atlas Network (HTAN, humantumoratlas.org) via the implementation of three-dimensional (3D) imaging technologies that will allow for a comprehensive view of the dynamic multidimensional ecosystems that define tumors in humans. Each project will lead to the multiplexed 3D characterization of at least one cancer transition investigated by the HTAN (pre-malignant to malignant, primary to metastatic, therapy responsive to resistant). The data and analytical tools generated through this FOA will be made available for use by the research and clinical communities through the activities of the HTAN Data Coordinating Center.

The Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project that represents a change in research direction for an early stage investigator (ESI) and for which no preliminary data exist. Applications submitted to this Funding Opportunity Announcement (FOA) must not include preliminary data. Applications must include a separate attachment describing the change in research direction.

The International Foundation for Ethical Research (IFER) is pleased to call for pre-proposal applications for its 2013 Graduate Student Fellowships for Alternatives to the Use of Animals in Science. The fellowships provide up to $12,500 annually in stipendiary support and up to $2,500 for supplies per year. The fellowships are renewable annually for up to three years. Continued funding is dependent on student progress and availability of funds.

In September, Miami received notice from the government that our new F&A rates are: 44.5% for On Campus Organized Research 44.0% On Campus Sponsored Instruction 39.0% On Campus Other Sponsored Activities 26.0% Off Campus All Programs These rates are effective beginning September 1, 2014. Awards received beginning in September and all proposal submissions going forward will be required to use the new rates.

PCORI seeks to fund pragmatic clinical trials, large simple trials, or large-scale observational studies that compare two or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving healthcare system-level approaches to managing care; communicating or disseminating research results to patients, caregivers, or clinicians; or eliminating health or healthcare disparities. Proposed studies must address critical clinical choices faced by patients, their caregivers, clinicians, or delivery systems. They must involve broadly representative patient populations and be large enough to provide precise estimates of hypothesized effectiveness differences and to support evaluation of potential differences in treatment effectiveness in patient subgroups.

Unlike other Dream Team grants offered by SU2C in recent years that focused on specific types of cancer, such as colorectal cancer or lung cancer, the SU2C Dream Team Translational Cancer Research Grant program is open to any type of translational cancer research. The program will support a single translational cancer research project that will address critical problems in patient care and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators.